DOSAGE — RESEARCH CONTEXT
BPC-157 TB-500 Dosage in the Research Literature
What animal models administered, by which route, over what duration — and why there is no validated human dose, no validated blend dose, and no controlled-trial injection schedule.
BPC-157 and TB-500 Dosage in the Research Literature
BPC-157 TB-500 dosage has no validated human figure, and no validated figure for the blend. Everything below is research context — what was administered to which species, by which route — never a human-use instruction. The framing throughout is "studied at X in [species]," because that is all the literature supports.
The BPC-157 component, in animal models only, is commonly expressed per body weight: rodent studies frequently used roughly 10 microg/kg and 10 ng/kg, and gastric-ulcer cytoprotection was studied at 400-800 ng/kg in rats [1]. The flagship transected-rat-Achilles tendon result used 10 microg/kg or 10 ng/kg intraperitoneally [1].
The TB-500 / Thymosin Beta-4 component spans a wide range. A rat embolic-stroke dose-response study used 2-18 mg/kg intraperitoneally, modeled an optimum near 3.75 mg/kg, and found that 18 mg/kg gave no benefit — higher is not better [4]. A six-month mdx muscular-dystrophy study used 150 microg twice weekly intraperitoneally [4]. Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend or the 7-mer [12].
Commercial "Wolverine" labeling commonly pairs the two at fixed combined masses per vial (e.g. ~10 mg BPC-157 + ~10 mg TB-500), but no peer-reviewed combination dose-finding study exists [8][9]. See the BPC-157 and TB-500 research findings for the studies these doses come from.
Oral vs Injectable BPC-157 and TB-500 in Research Handling
BPC-157 TB-500 oral handling is one of the most-asked route questions, and the honest answer separates the two constituents again. BPC-157 is studied as a notably stable "gastric" peptide and has been administered perorally in research; the underlying rodent efficacy studies for both peptides used predominantly intraperitoneal dosing, and human Phase 1 work on full-length Thymosin Beta-4 used the intravenous route [1][4][12].
The routes documented across the individual-compound literature are subcutaneous and intramuscular (the predominant research-community routes for the blend, not from controlled human trials), intraperitoneal (the rodent efficacy studies), intravenous (human Phase 1 of full-length Thymosin Beta-4; a BPC-157 IV safety pilot), local or intra-lesional and topical (individual-compound wound and tendon models), and oral (BPC-157 as a stable gastric peptide) [4][12]. Marketed blend oral products lack validated pharmacokinetics [8].
How Do You Reconstitute a BPC-157 / TB-500 Blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [8]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. This is research-handling context, not a human-use instruction.
Reconstitution in Research Handling
In research handling, both peptides are dissolved from freeze-dried powder in a diluent such as bacteriostatic water and kept refrigerated; a common community practice reconstitutes the two separately or in a shared vial [8]. The fragment-versus-full-length identity caveat around TB-500 compounds the uncertainty about what is actually in unregulated material [4].
Half-Life and Pharmacokinetics
The half-life and pharmacokinetics of the blend are not characterized in humans for either constituent. What exists is sparse and animal-weighted.
What Is the Half-Life of BPC-157 and TB-500?
No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study [1]. Human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but no specific half-life is established for the TB-500 heptapeptide [12].
Administration Frequency in Research Protocols
There is no validated injection schedule for the blend. Underlying rodent studies used a range of dosing — for example, Thymosin Beta-4 at 150 microg twice weekly intraperitoneally for six months in one model [4]. Community "loading then maintenance" protocols have no controlled-trial basis.
How Often Should You Inject BPC-157 and TB-500?
There is no validated injection frequency. The underlying studies vary by model and species; community schedules are not derived from controlled human trials [4]. The literature supports describing what was administered in animals, not recommending a human frequency.
How Do You Cycle BPC-157 and TB-500?
No validated cycle exists. Community "loading then maintenance" blend protocols and fixed-ratio vials (e.g. 10 mg + 10 mg) have no basis in controlled human trials and should not be presented as validated dosing [8][9]. Underlying study durations vary widely by model.